Insider · CIK 0001836430
James George Chopas
officer
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Jan 14, 2025, latest Jan 23, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 9
$0 bought, $180k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Apellis Pharmaceuticals, Inc. | $45k 2,064 shares | -4% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $14k 726 shares | -1% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $19k 873 shares | -2% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $4,572 189 shares | -0% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $15k 548 shares | -1% | - | |
| 23Weak | Apellis Pharmaceuticals, Inc. | $4,543 183 shares | -0% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $33k 1,096 shares | -2% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $21k 715 shares | -2% | - | |
| 30Weak | Apellis Pharmaceuticals, Inc. | $22k 783 shares | -2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 28, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +16,150 | $0.00 | $0 | 65,955 | Jan 30, 2026 |
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,064 | $21.77 | $45k | 49,805 | Jan 23, 2026 |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -726 | $19.79 | $14k | 51,869 | Jan 21, 2026 |
| Jan 13, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -873 | $22.19 | $19k | 52,595 | Jan 15, 2026 |
| Sep 15, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -189 | $24.19 | $4,572 | 53,468 | Sep 17, 2025 |
| Sep 2, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -548 | $28.08 | $15k | 53,657 | Sep 3, 2025 |
| Jun 18, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 54,205 | Jun 20, 2025 |
| Jun 9, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +11,250 | $19.39 | $218k | 11,250 | Jun 11, 2025 |
| Mar 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -183 | $24.82 | $4,543 | 47,955 | Mar 18, 2025 |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,096 | $30.43 | $33k | 48,138 | Jan 23, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -715 | $29.96 | $21k | 36,643 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +12,591 | $0.00 | $0 | 49,234 | Jan 21, 2025 |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -783 | $28.70 | $22k | 37,358 | Jan 14, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.